Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free GRAY Stock Alerts

Graybug Vision (GRAY) Competitors

Graybug Vision logo
$0.63 0.00 (-0.17%)
As of 05/22/2026
Compare

GRAY vs. VCNX, DCOY, CANF, ASLN, and HEPA

Should you buy Graybug Vision stock or one of its competitors? MarketBeat compares Graybug Vision with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Graybug Vision include Vaccinex (VCNX), Decoy Therapeutics (DCOY), Can-Fite BioPharma (CANF), ASLAN Pharmaceuticals (ASLN), and Hepion Pharmaceuticals (HEPA).

How does Graybug Vision compare to Vaccinex?

Graybug Vision (NASDAQ:GRAY) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Vaccinex has lower revenue, but higher earnings than Graybug Vision. Graybug Vision is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Graybug Vision$426.96M0.00-$35.60M-$24.23N/A
Vaccinex$388K6.70-$20.25M-$48.27N/A

Vaccinex's return on equity of 0.00% beat Graybug Vision's return on equity.

Company Net Margins Return on Equity Return on Assets
Graybug VisionN/A -77.61% -71.34%
Vaccinex N/A N/A -383.58%

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 7.9% of Graybug Vision shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

In the previous week, Graybug Vision's average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company Overall Sentiment
Graybug Vision Neutral
Vaccinex Neutral

Summary

Vaccinex beats Graybug Vision on 6 of the 10 factors compared between the two stocks.

How does Graybug Vision compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Graybug Vision (NASDAQ:GRAY) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Decoy Therapeutics has higher earnings, but lower revenue than Graybug Vision. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decoy TherapeuticsN/AN/A-$12.52M-$106.90N/A
Graybug Vision$426.96M0.00-$35.60M-$24.23N/A

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Graybug Vision's return on equity of -77.61% beat Decoy Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Decoy TherapeuticsN/A -395.42% -193.30%
Graybug Vision N/A -77.61%-71.34%

Decoy Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 310.96%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Decoy Therapeutics is more favorable than Graybug Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Decoy Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Graybug Vision
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Decoy Therapeutics had 3 more articles in the media than Graybug Vision. MarketBeat recorded 3 mentions for Decoy Therapeutics and 0 mentions for Graybug Vision. Decoy Therapeutics' average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score.

Company Overall Sentiment
Decoy Therapeutics Neutral
Graybug Vision Neutral

Summary

Graybug Vision beats Decoy Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Graybug Vision compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Can-Fite BioPharma currently has a consensus target price of $42.50, suggesting a potential upside of 1,150.00%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Graybug Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Graybug Vision
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Can-Fite BioPharma's return on equity of 0.00% beat Graybug Vision's return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Graybug Vision N/A -77.61%-71.34%

Can-Fite BioPharma has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Can-Fite BioPharma has higher earnings, but lower revenue than Graybug Vision. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K5.50-$7.63M-$35.80N/A
Graybug Vision$426.96M0.00-$35.60M-$24.23N/A

In the previous week, Can-Fite BioPharma's average media sentiment score of 0.34 beat Graybug Vision's score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Can-Fite BioPharma Neutral
Graybug Vision Neutral

Summary

Can-Fite BioPharma beats Graybug Vision on 8 of the 14 factors compared between the two stocks.

How does Graybug Vision compare to ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of Graybug Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Graybug Vision's return on equity of -77.61% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
Graybug Vision N/A -77.61%-71.34%

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
Graybug Vision Neutral

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Graybug Vision has higher revenue and earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
Graybug Vision$426.96M0.00-$35.60M-$24.23N/A

Summary

ASLAN Pharmaceuticals and Graybug Vision tied by winning 5 of the 10 factors compared between the two stocks.

How does Graybug Vision compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Graybug Vision has higher revenue and earnings than Hepion Pharmaceuticals. Graybug Vision is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Graybug Vision$426.96M0.00-$35.60M-$24.23N/A

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Graybug Vision Neutral

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Graybug Vision's return on equity of -77.61% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Graybug Vision N/A -77.61%-71.34%

Summary

Graybug Vision beats Hepion Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Get Graybug Vision News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRAY vs. The Competition

Export
MetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$988K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio-0.361.4620.9925.66
Price / Sales0.00119.63556.5686.31
Price / CashN/A20.0743.4956.67
Price / Book0.387.5910.447.14
Net Income-$35.60M-$3.64M$3.57B$335.98M
7 Day Performance-4.29%3.01%6.39%4.11%
1 Month Performance7.60%76.62%3.53%2.52%
1 Year Performance-65.06%126.61%34.12%35.04%

Graybug Vision Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRAY
Graybug Vision
N/A$0.63
-0.2%		N/A-65.1%$988K$426.96MN/A27
VCNX
Vaccinex
N/A$1.10
flat		N/A+47.0%$2.76M$388KN/A40
DCOY
Decoy Therapeutics
1.9221 of 5 stars		$4.41
-2.4%		$30.00
+580.3%		N/A$2.40MN/AN/A20
CANF
Can-Fite BioPharma
2.4098 of 5 stars		$3.36
-3.7%		$42.50
+1,164.9%		-83.6%$2.20M$405KN/A8
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat		N/AN/A$1.23M$12MN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GRAY) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Trump Is Eyeing the Biggest Monetary Shift Since Nixon
On August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...
Americas Gold Company | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
June 4: The day smart money moves (not June 12)
Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel